Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 1999

View Archived Issues

Naloxone's capacity to prevent adverse cognitive effects of ECT assessed

Activity of a glycopeptide antibiotic assessed in vitro and in vivo

Liposomal clofazimine assessed in murine tuberculosis

Hair growth promoters developed at Shiseido

Phase II trial expanded for Aronex's renal cell carcinoma product

Pfizer prepares new class of MMP inhibitors with hydroxamic acid structure

Preparation and use of P2T receptor antagonists in AstraZeneca's portfolio

Selective glucocorticoid receptor modulators emerge from Abbott-Ligand collaboration

Protease-inhibitory cephams and cephems and their use patented by Pliva

Synsorb Biotech searches for treatments for bacterial toxin-induced diseases

VUF-K-8788: new antiallergic agent characterized in experimental studies

Selective muscarinic M4 receptor blockade as potential new treatment option for PD

LifeTime and Arkios enter oncology alliance

Merck & Co. launches preservative-free HBV vaccine

Celgene reports initial results for phase II ADD/ADHD Rx trials

Oxagen broadens collaboration in IBD research

Korean researchers investigate novel 1beta-methylcarbapenems

Hollis-Eden updates progress of HE-2000 clinical trials

New acylquinoline selected for development as antiulcer agent by Korean investigators

Medinox's NOX-100 demonstrates potential as treatment of hemorrhagic shock

LEX-032, a recombinant serpin with beneficial effects on ischemia/reperfusion-induced pancreatitis

Synaptic and Merck & Co. discontinue development of oral treatment for BPH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...